PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Claim construction checkpoints: Application as filed versus granted patent (T 0715/24)

  • Technology: Biologics
  • 16th September 2026
G 1/24 requires that the description must always be “consulted” to interpret a claim. The question remains whether a definition in the description can override an otherwise clear meaning in the claims. In T 0715/24, Bristol-Myers Squibb (BMS) sought to persuade the Board of Appeal that a negative feature, read together with a paragraph of the description, gave the word “monotherapy” for a cancer treatment an unusual meaning that found basis in the application as filed. The Board of Appeal was not persuaded that the description of the granted patent could be used to alter the definition of monotherapy as it is normally understood in the art. On that ordinary reading, the claim was found to add matter over the application as filed.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Originally posted on IPKat.

This decision comes as we await the Enlarged Board of Appeal (EBA) response to G 1/26 on claim interpretation and added matter. The Board of Appeal in this case appeared to have no issues with how G 1/24 should be applied, or with the principle that a claim can add matter in view of the application as filed when read in the context of the description of the granted patent. 

Legal background on claim construction, added matter and G 1/24

Article 123(2) EPC prohibits amendments that introduce subject-matter extending beyond the content of the application as filed. The test is the “gold standard” confirmed by the EBA in G 2/10. An amendment is allowable only within the limits of what a skilled person would derive “directly and unambiguously, using common general knowledge, and seen objectively and relative to the date of filing, from the whole of the application as filed” (r. 9). It is, infamously, an unforgiving standard. Before it can be applied, however, the claim must first be construed. The question of added matter, as the Board of Appeal put it in the present case, “can only be answered on the basis of a proper construction of the claim” (r. 1).

In G 1/24, the EBA held that the description and drawings shall always be consulted to interpret the claims, and not only where a claim is unclear. What the EBA arguably did not settle in G 1/24 was what “consulting” the description actually entails, and in particular whether a definition in the description can be used to give a claim term a meaning it would not otherwise bear. That purportedly unresolved question has now generated its own referral. In G 1/26, the EBA has been asked how far description definitions can influence an assessment of added matter. 

Case background: Checkpoint inhibitors 

Nivolumab (BMS’s OPDIVO) is one of the anti-PD-1 checkpoint inhibitors that has reshaped the treatment of melanoma and other solid tumours. The commercial stakes are large. The global net sales for OPDIVO were $10 billion in 2025. OPDIVO is now also marketed in combination with the anti-LAG-3 antibody relatlimab (OPDUALAG), approved in 2022, which reached $1.2 billion in global net sales in 2025. The 480 mg dose of nivolumab is indicated in the approved labels for both OPDIVO and OPDUALAG.

The case in T 0715/24 concerned EP 3288980, owned by BMS, relating to the treatment of PD-L1-positive melanoma using an anti-PD-1 antibody. Opposed by five Opponents, inter alia for added matter, the patent was revoked by the Opposition Division. Three Opponents (respondents III, IV and V) took part in the appeal.

Claim 1 of the main request was directed to “a composition comprising nivolumab for use in treating a melanoma” in a PD-L1-positive patient, “to be administered a flat dose of 480 mg of nivolumab as monotherapy once every four weeks”, with a negative feature stating that the patient is not administered a combination of nivolumab and an anti-CTLA-4 antibody (such as ipilimumab).

The negative limitation introduced into the claim makes commercial sense. “Monotherapy” might be considered to exclude the newer OPDUALAG relatlimab + nivolumab combination. However, a look at the approved label for OPDIVO reveals how the monotherapy language found its way into the claim. The label makes a clear distinction between nivolumab “monotherapy” and nivolumab combined with the CTLA-4 inhibitor ipilimumab. A combination with relatlimab is not contemplated in the patent or the OPDIVO label. With this patent, BMS may have wished to cover both of their marketed nivolumab products, each of which uses the 480 mg nivolumab dose, either alone (OPDIVO) or in combination with relatlimab (OPDUALAG).

Interpretation of the claim in view of the granted patent

Both sides accepted the ordinary meaning of monotherapy as treatment with a single drug (r. 4). The Patentee argued that the term in the claim should be understood as excluding only the combination with an anti-CTLA-4 antibody, whilst permitting other drugs (e.g. relatlimab). This was how the claim was originally drafted:

“1. A method for treating a melanoma comprising:

(i) identifying a patient having a PD-L1 positive melanoma tumor; and

(ii) administering to the patient an anti-PD-1 antibody or an antigen-binding portion thereof that binds specifically to a human PD-1 (“anti-PDl antibody monotherapy”), wherein the patient is not administered a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof that binds specifically to a human CTLA-4 (“combination therapy”).”

This limitation and interpretation seem to be an attempt by BMS to align the meaning of “monotherapy” in the claim with how it is used in the OPDIVO label, i.e. to distinguish it from the combination with ipilimumab, but to still cover combination with other drugs such as the on-market combination with relatlimab.

The granted claim narrowed the disclaimer. Where the claim as filed excluded a combination of any anti-PD-1 antibody with an anti-CTLA-4 antibody, the granted claim excluded only a combination of “nivolumab and an anti-CTLA-4 antibody”. 

On claim construction, the Patentee argued that, read as a whole, the patent pointed to a special definition of “monotherapy” in paragraph [0040]. Paragraph [0040] stated: “The term ‘anti-PD-1 antibody monotherapy’ as used herein includes a therapy of an anti-PD-1 antibody without an anti-CTLA-4 antibody therapy.” The Patentee also argued that the negative feature in the claim also modified the definition of monotherapy.

The Board of Appeal was, however, not persuaded. Interpreting the claim “with a mind willing to understand” (r. 5), the Board of Appeal found the negative feature did no defining work. In the words of the Board of Appeal, “The negative feature is not drafted as a definition … against the well-recognised meaning of ‘monotherapy’ it merely introduces a fundamental ambiguity” (r. 7).

Nor did paragraph [0040] define the term, thought the Board of Appeal. This paragraph merely listed embodiments and did so for “anti-PD-1 antibody monotherapy” in general, not “nivolumab as a monotherapy”. The term “monotherapy” was not mentioned specifically in the paragraph. 

For the Board of Appeal, “monotherapy” therefore kept its usual meaning, and the skilled person would understand it in the context of the claim as meaning nivolumab used as a single drug. The original claim as filed was, critically, not used to interpret the claim of the granted patent.

Added matter in view of the application as filed

Given the construction of monotherapy according to its ordinary meaning, the question became whether that interpretation added matter. The Opponents first attacked the wording of the negative feature itself as added matter. However, the Board of Appeal expressly declined to decide that point. The objection that succeeded was aimed instead at the combination of features produced by the construction of monotherapy, i.e. monotherapy plus the specified dose and selected anti-PD-1 antibody. The question instead was whether the application as filed disclosed, directly and unambiguously, nivolumab for treating PD-L1-positive melanoma as an ordinary-sense monotherapy at the claimed flat dose.

Notably, the Board of Appeal considered how claim 1 as originally filed had defined “anti-PD-1 antibody monotherapy” in contradistinction to “combination therapy”, in quotation marks: “The use of quotation marks and parenthesis indicates that monotherapy is being assigned a specific definition in claim 1 as filed” (r. 13). Importantly for the Board of Appeal, this special meaning was not the usual one now in the granted claim, a reading reinforced by claim 49 as filed, which contemplated administering a further anti-cancer agent (r. 14). In contrast to the granted claim, the original claim was therefore considered to have an altered definition of monotherapy.

“[Claim 49] is thus consistent with the special definition of monotherapy set out in claim 1 as filed, according to which the administration of additional therapeutic agents is not excluded, provided that the patient is not administered the combination of nivolumab and an anti-CTLA-4 antibody.” (r. 14)

Crucially, this was not considered to change how the granted claim should be interpreted. Instead, it was found to support the argument that the granted claims added matter.

The key issue for the Patentee was therefore that monotherapy according to its ordinary meaning had not been unambiguously disclosed, in the view of the Board of Appeal, in combination with the selection of nivolumab and the specifically claimed dose. The Board of Appeal accepted that the claims as originally filed used an altered definition of monotherapy. However, the claim was considered to have been so amended that a skilled person, reading it in view of the granted patent, would consider monotherapy to have its ordinary meaning. Auxiliary request 1, which redefined monotherapy positively as nivolumab “without another anti-cancer agent”, fell for the same missing link (r. 21). The appeal was dismissed and the patent revoked.

Analysis

The problem for the Patentee in this case was that they used an unusual definition of a term in the original claims that they were unable to persuade the Board of Appeal could be combined with specific limitations later added to the claim. Another warning against using “unusual definitions”, and the particularly unforgiving nature of the EPO’s added matter test. The present case thus drew a key distinction, namely interpretation in view of the description as granted versus the application as filed. The claim was construed in the light of the description of the granted patent. Basis was tested against the application as filed, including the original claims.

G 1/26 asks the EBA whether the order that the description must always be consulted also applies when a claim is tested for added matter. In effect, the question is whether a patentee may invoke a description definition to construe a claim into a shape that has basis as filed and so escape an objection the prima facie wording would attract. T 0715/24 is tangentially relevant. The Board of Appeal consulted the description, as G 1/24 requires, and held that consultation neither defined the term nor cured the ambiguity. T 0715/24 nonetheless leaves plenty else that may be considered in G 1/26. In particular, the Board of Appeal never had to decide whether a description definition can rescue a claim because it found that there was no definition to apply. G 1/26 concerns the harder case in which the description is found to explicitly define the disputed term.

It is a welcome change to have a G 1/24 related case that can be mapped onto the commercial consequences (does anyone in the real world care if the tobacco in cigarettes is gathered or spiralled…?). The shifting definitions at play in this case make perfect sense when the on-market products are considered. Had the patent survived, it would have been interesting to see how courts might have chosen to interpret “monotherapy” in infringement proceedings.

Author: Rose Hughes

Rose Hughes

Rose is a biotech and pharmaceutical patent specialist with over a decade of experience in intellectual property. Rose is a Patent Director at Evolve, where she leverages our unique fractional in-house model to provide clients with deep patent law expertise combined with the strategic commercial oversight typically associated with senior in-house counsel.

With a PhD in Immunology from UCL, Rose applies her technical background to complex innovations in biologics, cell and gene therapies, and the rapidly emerging field of AI-assisted drug development. Previously, Rose held the role of Director, Patents at AstraZeneca, where she was responsible for global IP portfolios and IP strategy at every stage of the pharmaceutical pipeline, from platform development and on-market commercialisation to SPCs and patent term extensions.

A recognised thought leader in the field, Rose has been a regular contributor to IPKat since 2018, offering practical insights into European patent law developments. She is also a frequent speaker on the epi podcast, a guest lecturer for the Brunel University IP law Postgrad Certificate, and a contributing author to published books A User’s Guide to Intellectual Property in Life Sciences (2021) and Developments and Directions in Intellectual Property Law (2023).

Related insights...

Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Any inhibitor will do: Functional claims do not always need to be limited by modality (T 1355/24)

  • 5th November 2026
How much data does a Patentee need to claim every molecule that hits a target? For antibodies, the Boards of Appeal have long accepted that identifying a new target or epitope can justify a claim to the whole functional genus of antibodies that bind it. The recent decision in T 1355/24 extends that generosity to…
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image

Prophetic prior art and the common light chain mouse (T 0527/24)

  • 1st November 2026
Kymab is famous as the Cambridge antibody mouse company that fought Regeneron all the way to the UK Supreme Court, and won, on sufficiency (no mean feat, given the very strict approach the UK courts have taken to the sufficiency test for pharmaceutical inventions in recent years). In T 0527/24, Kymab was on the other…
Gold antibody shape with one glowing turquoise arm tip on dark blue, Evolve abstract article image.
Gold antibody shape with one glowing turquoise arm tip on dark blue, Evolve abstract article image.

Be careful what you wish for: Method of treatment claim for an antibody genus found to satisfy both written description and enablement requirement (Teva v Eli Lilly)

  • 3rd July 2026
In a remarkable departure from what we might have expected it to do following Amgen v Sanofi, the US Court of Appeals for the Federal Circuit in Teva v Eli Lilly upheld a jury verdict finding that a method of treatment claim for a broad genus of antibody satisfied both the written description and enablement…
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image

Human definitions versus biological reality (T 630/24)

  • 16th June 2026
As the recent furore over claim interpretation and description amendments illustrates, patent attorneys love nothing more than to argue about the meaning of words. As we know, words are contextual things, and can shift their meaning depending on the words around them and the perspective of the reader. Definitions are particularly unstable in biological sciences,…
Straight gold ladder with one glowing turquoise rung on dark blue, Evolve abstract article image.
Straight gold ladder with one glowing turquoise rung on dark blue, Evolve abstract article image.

Sequence identities and functional definitions – where is the limit? (T 0137/24)

  • 2nd June 2026
Biotechnology patents often rely on defining protein and nucleic acid features by their sequence identity. However, it is often not necessary to define the exact sequence, but instead to define the sequence according to a limit of sequence identity, e.g. a sequence having a 90% sequence identity to a specified sequence.
Gold bar carrying turquoise cubes on slender stalks on dark blue, Evolve abstract article image.
Gold bar carrying turquoise cubes on slender stalks on dark blue, Evolve abstract article image.

Strict US written description and enablement requirement applied to ADCs and platform inventions (Seagen v Daiichi Sankyo)

  • 14th December 2025
The recent decision of the US Court of Appeals for the Federal Circuit in Seagen v Daiichi Sankyo overruled the jury decision in the District Court to find an ADC linker platform patent invalid for both lack of written description and enablement. 
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image

UPC Court of Appeal tackles broad functional antibody claims (UPC_CoA_529/2024)

  • 4th December 2025
The global litigation saga involving Amgen’s PCSK9 antibodies has long served as a high-stakes test case for jurisdictional approaches to broad, functionally defined antibody claims. Following the US Supreme Court’s landmark finding of lack of enablement in Amgen v Sanofi, and the UPC Munich Central Division’s initial revocation of the equivalent European patent, all eyes…
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image

EPO pharma case law trends 2025: Antibodies and biologics

  • 19th November 2025
The science of biologics is rapidly progressing, with the development of ever more complex protein structures, incorporation of molecules into cell therapies and the increasing use of AI-assisted design and in silico modelling. Patent law must respond to these new challenges. What better time to take a look at the trends from the EPO case…
Straight gold ladder with one glowing turquoise rung on dark blue, Evolve abstract article image.
Straight gold ladder with one glowing turquoise rung on dark blue, Evolve abstract article image.

Alexion’s Soliris sequence error saga (Alexion v Samsung Bioepis [2025] EWHC 1240)

  • 4th June 2025
Beware! The recent Samsung v Alexion UK High Court decision reveals that even a single-letter error in patent sequence data, coupled with vague descriptive language, can invalidate your claims and lead to costly legal battles.
Gold antibody shape with one glowing turquoise arm tip on dark blue, Evolve abstract article image.
Gold antibody shape with one glowing turquoise arm tip on dark blue, Evolve abstract article image.

First UPC decision to tackle infringement and validity of second medical use claims (Sanofi v Amgen, UPC_CFI_505/2024)

  • 19th May 2025
Understand the UPC’s first ruling on second medical use patents, which clarifies novelty and infringement standards but creates new hurdles for patentees, especially concerning “skinny labelling” and proving off-label use.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice